Cash PositionBenitec Biopharma ended the quarter with $103.6M in cash, believed to be sufficient to fund operations for 18 to 24 months.
Clinical TrialsBB-301 showed compelling clinical data, improving dysphagia measures with no serious adverse events.
Financial PerformanceBenitec Biopharma recorded a net loss of only $0.24 per share, better than the forecasted loss of $0.36 per share.